Guidelines and PILs
- 08/03/2023
- Polypharmacy in older people EqHIA.pdf
-
-
- 05/01/2023
- Maximising the opportunity presented by biosimilar medicines - A national strategy for Wales.pdf
-
-
-
- 15/12/2022
- Guide to collaborative working between NHS, primary care contractors and the pharmaceutical industry
-
-
- 15/12/2022
- Value-based prescribing - EqHIA.pdf
-
-
- 20/06/2022
- Value-based prescribing - Strategy.pdf
-
-
- 31/12/2018
- Medicines Identified as Low Priority for Funding in NHS Wales - Paper 2
-
-
-
The aim of these documents is to minimise the prescribing of medicines that offer a limited clinical benefit to patients and where more cost effective treatments may be available.
Four medicines/medicine groups have been identified for the purposes of this document: omega-3 fatty acid compounds, oxycodone and naloxone combination product, paracetamol and tramadol combination product and perindopril arginine.
- 05/07/2022
- Tramadol leaflet B (Welsh) - 072022.pdf
-
-
- 05/07/2022
- Tramadol leaflet B (English) - 072022.pdf
-
-
- 05/07/2022
- Tramadol leaflet A (Welsh) - 072022.pdf
-
-
- 05/07/2022
- Tramadol leaflet A (English) - 072022.pdf
-
-